hide
Free keywords:
-
Abstract:
Background
Cell culture-based production of influenza vaccine remains an attractive alternative to eggbased production. Short response time and high production yields are the key success factors for the broader adoption of cell culture technology for industrial manufacturing of pandemic and seasonal influenza vaccines. Recently, HEK293SF cells have been successfully used to produce influenza viruses, achieving hemagglutinin (HA) and infectious viral particle (IVP)titers in the highest ranges reported to date. In the same study, it was suggested that beyond 4x 106 cells/mL, viral production was limited by a lack of nutrients or an accumulation of toxic products.
Results
To further improve viral titers at high cell densities, erfusion culture mode was evaluated. Productivities of both perfusion and batch culture modes were compared at an infection cell density of 6 x 106 cells/mL. The metabolism, including glycolysis, glutaminolysis and amino acids utilization as well as physiological indicators such as viability and apoptosis were extensively documented for the two modes of culture before and after viral infection to
identify potential metabolic limitations. A 3L bioreactor with a perfusion rate of 0.5 vol/day allowed us to reach maximal titers of 3.3 x 1011 IVP/mL and 4.0 logHA units/mL,
corresponding to a total production of 1.0 x 1015 IVP and 7.8 logHA units after 3 days postinfection. Overall, perfusion mode titers were higher by almost one order of magnitude over the batch culture mode of production. This improvement was associated with an activation of the cell metabolism as seen by a 1.5-fold and 4-fold higher consumption rates of glucose and glutamine respectively. A shift in the viral production kinetics was also observed leading to an accumulation of more viable cells with a higher specific production and causing an increase in the total volumetric production of infectious influenza particles.
Conclusions
These results confirm that the HEK293SF cell is an excellent substrate for high yield production of influenza virus. Furthermore, there is great potential in further improving the production yields through better control of the cell culture environment and viral production kinetics. Once accomplished, this cell line can be promoted as an industrial platform for costeffective manufacturing of outbreaks the influenza seasonal vaccine as well as for periods of peak demand during pandemics.
© 2011 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media. [accessed November 30th, 2011]
